Kymera Investor Day Presentation Deck
●
●
●
●
Our first 5 years; pipeline and platform investments
Three compelling clinical programs with large franchise potential:
IRAK4, KT-474 - Ph1 data de-risks profile for best-in-class oral drug in broad immune-inflammatory indications
IRAKIMID, KT-413 - Potential for first therapeutics for genetically defined subtype of DLBCL, IND cleared
STAT3, KT-333 - First specific degrader against a transcription factor with large franchise potentials, IND cleared
Significant investment in our discovery pipeline:
MDM2, KT-253 - Best in class P-53 stabilizer for liquid and solid tumors, IND in 2022
Commitment to at least 1 new IND/year, yearly disclosure of new development program(s)
Commitment to innovation for our platform and pipeline:
●
●
●
●
●
●
What We Showed You Today
●
First tissue restricted E3 ligase in vivo POC, leading to tissue sparing biology
Novel approach to molecular glue for undrugged/unligandable targets
Goal of drugging all target classes in the cell
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
KYMERA R&D DAY - December 16th, 2021
PAGE 99View entire presentation